Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Trodelvy (sacituzumab govitecan-hziy by Year
Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) ($M) ($M)
Gilead Sciences Trodelvy (sacituzumab govitecan-hziy: $1,397M in FY2025, up 6.2% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trodelvy (sacituzumab govitecan-hziy — TROP-2 ADC) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,397 | +6.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1,315 | +23.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,063 | +56.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 680 | +78.9% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 380 | +675.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 49 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up trodelvy (sacituzumab govitecan-hziy
Cite this data
StockData. (2026). Gilead Sciences Trodelvy (sacituzumab govitecan-hziy ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-trodelvy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.